“We are excited about the potential to advance a novel treatment for early Alzheimer’s disease with convenient oral dosing and our team remains deeply committed to executing on our momentum,” said Christopher U Missling, PhD, President and CEO. “I am proud of the strides the Anavex (AVXL) team has made in the recent quarter to potentially making a difference for individuals suffering from Alzheimer’s disease, by presenting a scalable treatment alternative alongside the ease of oral administration.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Anavex receives EMA filing acceptance for treatment of Alzheimer’s disease
- Options Volatility and Implied Earnings Moves Today, December 23, 2024
- Options Volatility and Implied Earnings Moves This Week, December 23 – December 26, 2024
- Biotech Alert: Searches spiking for these stocks today
- Anavex announces upcoming presentation of data from ATTENTION-AD study